Document is current
Any future updates will be listed below
-
Authors
Chakravarty, Antara https://orcid.org/0000-0001-5440-990X
Wang, Lu-Ning https://orcid.org/0000-0002-3908-7946
Golden, Ryan P. https://orcid.org/0009-0004-7113-007X
Li, Zhengnian https://orcid.org/0000-0001-5851-8011
Donovan, Katherine A. https://orcid.org/0000-0002-8539-5106
Afanzar, Oshri
Zhang, Yupeng
Fischer, Eric S. https://orcid.org/0000-0001-7337-6306
Gray, Nathanael S. https://orcid.org/0000-0001-5354-7403
Yang, Priscilla L. https://orcid.org/0000-0001-7456-2557
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01 AI148632)
- License Information
-
More Information
Article History
Received: 21 April 2025
Accepted: 28 January 2026
First Online: 10 February 2026
Competing interests
: P.L.Y. is a founder and science advisory board member (SAB) of Viraccio Therapeutics. N.S.G. is a founder, science advisory board member (SAB), and equity holder in Syros, C4, Allorion, Lighthorse, Inception, Matchpoint, Shenandoah (board member), Larkspur (board member), and Soltego (board member). The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield, Springworks, Interline and Sanofi. K.A.D. receives or has received consulting fees from Neomorph Inc. and Kronos Bio. E.S.F. is a founder, SAB and equity holder in Neomorph (board member), Civetta, Anvia (board member), Proximity, and Stelexis; consultant/SAB and equity holder in Ajax, Avilar, and Photys; equity holder in Lighthorse and CPD4 (board member). The Fischer lab has received or continues to receive research funding from Novartis, Astellas, Ajax, Deerfield, Springworks, and Interline. The remaining authors declare no competing interests.
